Vistagen Therapeutics, Inc.
Business
Vistagen Therapeutics is a late clinical-stage biopharmaceutical company developing intranasal pherine product candidates targeting neuropsychiatric and neurological disorders. The company's pipeline includes fasedienol for acute social anxiety disorder (Phase 3), itruvone for major depressive disorder (Phase 2), refisolone for menopausal hot flashes (Phase 2), PH15 for mental-fatigue-related psychomotor impairment (Phase 2), PH284 for cancer cachexia (Phase 2), and AV-101 for NMDAR-related disorders (partnered). Products are delivered via intranasal administration targeting nasal chemosensory neurons and specific brain neurocircuits. The company operates primarily in U.S. and select international markets through clinical trials and strategic partnerships.
Summary from 10-K filed 2026-06-15
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Total revenues | 1 | 486,000 | 1 | — | 1 | |
| Research and development | 55 | 39 | 20 | 44 | 35 | |
| General and administrative | 18 | 17 | 14 | 15 | 13 | |
| Total operating expenses | 73 | 56 | 34 | 59 | 49 | |
| Loss from operations | −72 | −56 | −33 | −59 | −48 | |
| Interest income, net | 2 | 5 | 3 | 26,000 | — | |
| Other income, net | 7,000 | 5,000 | 312,000 | 0 | — | |
| Loss before income taxes | −70 | −51 | −29 | −59 | −48 | |
| Income taxes | −7,000 | −7,000 | −4,000 | −6,000 | −3,000 | |
| Net loss | −70 | −51 | −29 | −59 | −48 | |
| Unrealized gain (loss) on marketable securities | −7,000 | 5,000 | 0 | — | — | |
| Comprehensive loss | −70 | −51 | −29 | −59 | — | |
| Loss per share, basic (in dollars per share) | −1.83 | −1.67 | −1.52 | −8.51 | −7.38 | |
| Loss per share, diluted (in dollars per share) | −1.83 | −1.67 | −1.52 | −8.51 | — | |
| Weighted average common shares outstanding, basic (in shares) | 38 | 31 | 19 | 7 | 7 | |
| Weighted average common shares outstanding, diluted (in shares) | 38 | 31 | 19 | 7 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 31 | 67 | 119 | 17 | 68 | |
| Marketable securities | 15 | 13 | 0 | — | — | |
| Prepaid expenses and other current assets | 2 | 2 | 2 | 802,000 | 3 | |
| Total current assets | 47 | 82 | 121 | 18 | 71 | |
| Property and equipment, net | 427,000 | 476,000 | 435,000 | 507,000 | 414,300 | |
| Right-of-use asset - operating lease | 801,000 | 1 | 2 | 2 | 3 | |
| Other assets | 393,000 | 454,000 | 726,000 | — | — | |
| Total assets | 49 | 84 | 124 | 21 | 75 | |
| Accounts payable | 2 | 653,000 | 2 | 2 | 3 | |
| Accrued expenses | 9 | 9 | 2 | 796,000 | 1 | |
| Notes Payable | 100,000 | 0 | — | — | — | |
| Deferred revenue - current portion | 2 | 3 | 791,000 | 714,000 | 1 | |
| Less: operating lease liabilities - current portion | 699,000 | 561,000 | 550,000 | 486,000 | 433,300 | |
| Total current liabilities | 13 | 13 | 5 | 5 | 6 | |
| Deferred revenue - non-current portion | 0 | 391,000 | 3 | 2 | 2 | |
| Operating lease liabilities - non-current portion | 249,000 | 948,000 | 2 | 2 | 3 | |
| Total liabilities | 13 | 14 | 9 | 9 | 10 | |
| Commitments and contingencies (Note 13) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2026 and March 31, 2025; no shares outstanding at March 31, 2026 and March 31, 2025 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.001 par value; 325,000,000 shares authorized at March 31, 2026 and March 31, 2025; 39,624,839 and 29,001,481 shares issued at March 31, 2026 and March 31, 2025, respectively | 40,000 | 29,000 | 27,000 | 7,000 | 6,900 | |
| Additional paid-in capital | 517 | 482 | 474 | 343 | 336 | |
| Treasury stock, at cost, 4,522 shares of common stock held at March 31, 2026 and March 31, 2025 | −4 | −4 | −4 | −4 | −4 | |
| Accumulated other comprehensive gain (loss) | −2,000 | 5,000 | 0 | — | — | |
| Accumulated deficit | −477 | −408 | −356 | −327 | −268 | |
| Total stockholders equity | 36 | 70 | 114 | 12 | 65 | |
| Total liabilities and stockholders equity | 49 | 84 | 124 | 21 | 75 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 199,000 | 150,000 | 127,000 | 130,000 | — | |
| Loss on disposal of fixed assets | 0 | 0 | 6,000 | 0 | — | |
| Stock-based compensation | 4 | 4 | 2 | 3 | 3 | |
| Amortization of operating lease right-of-use asset | 534,000 | 485,000 | 441,000 | 402,000 | 557,600 | |
| Accretion of marketable securities | −543,000 | −389,000 | 0 | — | — | |
| Prepaid expenses and other current assets | 36,000 | −88,000 | 250,000 | 3 | −2 | |
| Other assets | −46,000 | 190,000 | 0 | — | — | |
| Operating lease liability | −561,000 | −611,000 | −495,000 | −433,000 | −677,000 | |
| Deferred sublicense revenue, net of deferred contract acquisition costs | −1 | −412,000 | 516,000 | 206,000 | — | |
| Accounts payable and accrued expenses | 828,000 | 6 | 522,000 | −934,000 | 2 | |
| Net cash used in operating activities | −66 | −42 | −26 | −50 | −45 | |
| Purchases of laboratory and other equipment | −151,000 | −191,000 | −61,000 | −212,000 | −200,400 | |
| Sales and maturities of marketable securities | 22 | 12 | 0 | — | — | |
| Purchases of marketable securities | −22 | −25 | 0 | — | — | |
| Net cash used in investing activities | −877,000 | −13 | −61,000 | −740,000 | −200,400 | |
| Proceeds from issuance of common stock and warrants, net of issuance costs | 8,000 | 0 | 93 | 0 | — | |
| Issuance of note payable for insurance policy | 1 | 0 | — | — | 0 | |
| Repayment of note payable | −925,000 | 0 | −985,000 | −1 | 0 | |
| Net cash provided by financing activities | 31 | 3 | 128 | −1 | 10 | |
| Net increase (decrease) in cash and cash equivalents | −36 | −52 | 103 | −51 | −35 | |
| Cash paid for interest | 33,000 | 0 | — | — | 300 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Vistagen Therapeutics, Inc.'s CIK number?
Vistagen Therapeutics, Inc.'s SEC CIK number is 0001411685 (1411685). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Vistagen Therapeutics, Inc.'s SEC filings?
All of Vistagen Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Vistagen Therapeutics, Inc. last report earnings?
Vistagen Therapeutics, Inc. (VTGN) most recently filed an earnings 8-K with the SEC on Jun 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-043232). This is Vistagen Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Vistagen Therapeutics, Inc.'s most recent earnings 8-K?
Vistagen Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Jun 15, 2026 under accession 0001628280-26-043232. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Vistagen Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →